Drugs / PIKA rabies vaccine
PIKA rabies vaccine
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02657161 | Feb → Jul 2015 | rabies | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02956421 | Feb → Oct 2016 | rabies | Yisheng Biopharma (Singapore) Pte. Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05667974 | Sep 2023 → Mar 2024 | rabies | Yisheng Biopharma (Singapore) Pte. Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PIKA rabies vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02657161 ↗ |
| Action | Activate | “The PIKA Rabies vaccine adjuvant is a TLR3 agonist that activates B and T cells leading to a robust immune response.” PMID 28118938 ↗ Jan 2017 |
| Modality | Vaccine | “PIKA rabies vaccine exhibited a more significant enhancement in neutralizing antibody levels just 5 days post-vaccination, surpassing the immune response induced by licensed...” PMID 37821317 ↗ Oct 2023 |
| Route | Intramuscular | “The route of administration is intramuscular injection, given in the deltoid region of the arm.” NCT02956421 ↗ |
| Target | TLR3 | “The PIKA Rabies vaccine adjuvant is a TLR3 agonist that activates B and T cells leading to a robust immune response.” PMID 28118938 ↗ Jan 2017 |